Company intelligence / Profile preview

Spica Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

Spica Therapeutics is developing a pipeline based on its proprietary platform for targeting disease-relevant macrophage subsets. The company has two lead programs in oncology and fibroinflammatory diseases, aiming to address unmet medical needs by modulating specific immune cell populations. As of January 2025, the company had emerged from stealth mode and was advancing these programs toward the clinic; detailed clinical results have not yet been disclosed.

Therapeutic areas: OncologyImmunology
Modalities: Macrophage-targeting biologics (precise modalities not explicitly listed, but focus is on modulating macrophages using proprietary technology)
Industry: Biotech

Drug pipeline

1 asset

ST101

Preclinical

Partnerships

Supported by Bioqube Ventures’ venture creation model; no major pharma partnerships publicly disclosed as of May 2025.

Beyond the preview

Go deeper on Spica Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spica Therapeutics.